EP3551538B1 - Dispositif de préparation de solutions radioactives - Google Patents

Dispositif de préparation de solutions radioactives Download PDF

Info

Publication number
EP3551538B1
EP3551538B1 EP17811538.2A EP17811538A EP3551538B1 EP 3551538 B1 EP3551538 B1 EP 3551538B1 EP 17811538 A EP17811538 A EP 17811538A EP 3551538 B1 EP3551538 B1 EP 3551538B1
Authority
EP
European Patent Office
Prior art keywords
support block
syringe
cell
barrel
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17811538.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3551538A1 (fr
Inventor
Guénolé MATHIAS-LAOT
Quentin THOMAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Lorraine
Original Assignee
Universite de Lorraine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Lorraine filed Critical Universite de Lorraine
Publication of EP3551538A1 publication Critical patent/EP3551538A1/fr
Application granted granted Critical
Publication of EP3551538B1 publication Critical patent/EP3551538B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
    • G21F7/00—Shielded cells or rooms
    • G21F7/005—Shielded passages through walls; Locks; Transferring devices between rooms
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B3/00—Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B3/003—Filling medical containers such as ampoules, vials, syringes or the like
    • B65B3/006—Related operations, e.g. scoring ampoules
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21F—PROTECTION AGAINST X-RADIATION, GAMMA RADIATION, CORPUSCULAR RADIATION OR PARTICLE BOMBARDMENT; TREATING RADIOACTIVELY CONTAMINATED MATERIAL; DECONTAMINATION ARRANGEMENTS THEREFOR
    • G21F5/00—Transportable or portable shielded containers
    • G21F5/015—Transportable or portable shielded containers for storing radioactive sources, e.g. source carriers for irradiation units; Radioisotope containers
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G1/00—Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation or particle bombardment, e.g. producing radioactive isotopes
    • G21G1/0005—Isotope delivery systems

Definitions

  • the field of the invention is that of the preparation of radioactive solutions, and in particular of radiopharmaceuticals.
  • the invention relates more particularly to a device for preparing such radioactive solutions and radiopharmaceuticals.
  • radiopharmaceutical drugs contain artificial radioelements called radionuclides, which are used for diagnostic or therapeutic purposes and used in nuclear medicine departments. These drugs are either in the form of pharmaceutical specialties containing radionuclides which are delivered ready for use, or in the form of radiopharmaceutical preparations which are prepared in situ and extemporaneously by labeling of carrier molecules, designated under the term “kits” by those skilled in the art, with a selected radionuclide from a generator.
  • kits carrier molecules
  • the most frequently used radionuclide in nuclear medicine is technetium 99m ( 99m Tc), which is readily available from the 99m Mo / 99m Tc generator and which is administered as a sodium pertechnetate solution.
  • This solution is obtained by elution to give eluate of technetium 99m in the form of sterile and pyrogen-free solutions. More precisely, the vector molecules forming these kits are sterile and pyrogen-free substances, which are usually pre-packaged in the form of vacuum-sealed kit bottles.
  • shielded enclosures are generally used for the preparation of these medicaments, provided with openings of the round glove type on the edges of which are fixed latex gloves where the operators introduce their hands.
  • Certain centers use enclosures without integral gloves, replaced by traditional single-use latex or nitrile gloves worn by the user and changed at each handling. This practice is justified by the fact that gloves attached to the enclosure are too thick and interfere with the agility of preparers, who are more comfortable with traditional thin gloves. We thus play on the “time” factor to protect our from radiation.
  • the preparations are made by transferring a diluted eluate into the kit bottle using disposable syringes. Once the RPM solution has been prepared, and passage through the activity meter, a leaded syringe cover is installed on the syringe.
  • the object of the invention is to provide a device for the preparation of radiopharmaceuticals which enables automated preparation of radioactive solutions and minimizes the exposure of operators to the radiations emitted by the radionuclides.
  • the support block is configured so that it can also be brought into a position, called the closed position, in which the opening is closed by a shielded element carried by the support block.
  • the device equipped with several cells, makes it possible to carry out the preparations required for the use of RPM, whether it is for reconstitutions, labeling and fractionation, or simple dilutions and transfers between vials.
  • the use of the device is not limited to the preparation of RPMs, but can be employed for the preparation of any radioactive solution.
  • the shielded element carried by the support block can be integral therewith, for example if the support block is also made of a material making it possible to block or attenuate the radiation of the isotopes, or else attached to the latter.
  • the shielded element can for example be a disc made of lead-based material (or other suitable anti-radiation material) placed in a housing opening into an upper face of the mobile support block.
  • the shielded screed is made of any material making it possible to attenuate or block the passage of radiation emitted by the isotopes placed in the screed, for example lead, lead-based material, or other anti-radiation materials.
  • the thickness of the armored screed is adjusted according to the doses contained and the desired attenuation.
  • the movable support block is a cylindrical barrel mounted to rotate, preferably along a substantially central axis. vertical, and in which the cells open into the upper face of the barrel.
  • the cells and the housing of the shielded element are positioned in the barrel so as to be able to bring them selectively, by rotating the barrel, into alignment with the opening of the yoke.
  • the syringe actuating means comprises a first mobile with which the syringe holder is integral, the syringe holder ensuring the maintenance of the syringe body and a second mobile with means for coupling to the syringe piston.
  • the syringe actuation means is configured to either simultaneously move the first and second movable, or to move the second mobile relative to the first mobile.
  • the device also advantageously comprises translation means mounted on the first mobile, in order to move the syringe holder laterally with respect to the support block; and / or the syringe holder is associated with a support and comprises means for moving the syringe holder downward with respect to its support.
  • the present invention relates to a device for preparing radioactive solutions and in particular for radiopharmaceutical preparations allowing products to be taken from vials in an automated manner, and guaranteeing the safety of the user.
  • the device is in particular designed to allow the preparation of RPMs, in particular of RPM injections, combining a radioisotope with a vector, that is to say a molecule (or fragment) chosen to be located selectively on a particular structure of the organism.
  • the device for preparing RPM injections 10 which comprises a mobile support block 12 comprising several cells 14 capable of accommodating a vial.
  • the support block 12 is intended to accommodate various vials for reconstituting RPM or their fractionation, with a view to preparing injections.
  • the vials used are glass vials in penicillin vial format (example: diameter 2.5 cm, height 5.5 cm) provided with a rubber cover on the upper opening and called “kits”.
  • Other bottles can of course be used, and the dimensions of the cells 14 adapted accordingly.
  • the device advantageously comprises a protective case shielded around the support block.
  • the protective case is a "shielded" yoke 16, which comprises a side wall 18 surrounding the periphery of the support block 12 and an upper wall 20 covering the upper face 22 of the support block 12.
  • An opening 24 is provided in the upper wall 20 of the housing, to allow access to the cells 14.
  • the shielded cap 16 can be made of lead, for example with a thickness of the order of for example 9 to 30 mm or any other material making it possible to shield (attenuate or block) radionuclide emissions.
  • the wall thickness is chosen to attenuate ionizing radiation depending on the material used and the isotope dose.
  • the upper wall 20 of the yoke 16 is removable, to allow the loading / unloading of bottles in the cells 14.
  • Reference numeral 26 generally designates syringe actuating means configured to move a syringe vertically, substantially in the axis of the opening, and to actuate a plunger of said syringe, as described in more detail below.
  • the reference sign 27 designates a syringe holder for a syringe 29 (visible in figure 5 ).
  • the support block 12 is preferably produced as a rotary barrel, a term which will be adopted for the remainder of the description.
  • the device 10 comprises a means for driving the barrel 12 which is configured to selectively move the barrel 12 into positions, called working positions, in which a given cell 14 is aligned with the opening 24 to allow access to it. cell from outside the box 16.
  • the barrel 12 comprises a body of generally cylindrical shape, with a cylindrical lateral face 28 of axis A, the upper face 22 and a lower face 30. In the device, the barrel 12 is arranged with its lower face 30 facing downwards. .
  • the barrel 12 is rotatably mounted on a plate 32 which forms the base of the device 10 and also supports the armored yoke 16 (the plate 32 can be of anti-radiation material, but this is often not necessary because the device is placed on it. an armored support).
  • the plate 32 can be of anti-radiation material, but this is often not necessary because the device is placed on it. an armored support).
  • it comprises a central cylindrical housing 34 opening into the lower face 20, as seen in Fig. 4 .
  • An axis 36 extends perpendicularly to the plate 32 and engages in the housing 34.
  • the axis 36 has a diameter corresponding substantially to the internal diameter of the housing 34, up to the operating clearance, so as to allow rotation of the barrel. around axis 36 (coincident with axis A).
  • a crown 38 possibly toothed, surrounding the axis 36.
  • the crown 38 allows a drive in rotation, for example by belt (not shown), of the barrel 12 on the axis 34. This belt is also engaged on a drive pulley (not shown) integral with an output shaft of a barrel motor assembly 40, mounted on the plate 32.
  • the barrel 12 comprises four cells 14 (also designated individually 14.1 to 14.4) capable of receiving flasks for the preparation of solutions. These cells 14 are designed to open into the upper face 22 of the barrel 12.
  • the cells 14 are preferably of cylindrical shape (circular section or other), but advantageously have their axis (B) inclined relative to the vertical, for example of 15 to 20 °. This makes it easier to draw from the bottom of the vial when the remaining volume is low.
  • the diameter of the barrel 12, and the dimensions of the cells depend on the bottles to be received and therefore on the intended applications.
  • the cells 14 can have a depth between 35 and 70 mm.
  • the inlet diameter of the cells 14 is adapted to the vials and the passage section of the opening 24 is preferably slightly less than the inlet diameter of the cells 14.
  • the barrel 12 in fact comprises a fifth cell 15, called housing, designed to accommodate lead (the cell is empty on the Fig. 3 ).
  • a lead element 17 is thus placed in this housing 15, for example a disk or cylinder of a shape complementary to the housing ( Fig. 2 ) 15.
  • This lead element 17 makes it possible, when it is aligned with the opening 24, to close this opening 24 and constitutes a shielding which blocks the emission of radiation to the outside of the housing through the orifice 24.
  • the drive means constituted by the motor assembly 40 linked to the crown 38 allows the barrel 12 to be pivoted so as to be able to selectively align each of the cells 14.1 to 14.4 with the opening 22, thus allowing the 'access to the bottles contained in these cells from the outside of the box, forming the working positions.
  • the drive means also makes it possible to put the barrel 12 in the closed position, in which the housing 15 is aligned with the opening 24 and the lead element 17 closes the opening 24.
  • the barrel 12 can be made from any material and by any suitable process. In particular, it can be advantageously produced in a rigid polymer, such as ABS. 3D printing is an advantageous manufacturing technique, but other techniques can be employed.
  • the four cells 14.1 to 14.4 intended to receive vials and the cell 15 accommodating the lead disc 17 have the center of their upper openings, in the plane of the upper face 22 of the barrel, equidistant from the axis of rotation A. Of course, this distance is substantially the same as the distance from the axis A to the center of the opening 24. This therefore allows any of the cells 14.1 to 14.4 and 15 to be aligned as desired with the opening 24, by pivoting the barrel around of its axis.
  • the cell 14.4 comprises a tubular jacket closed at its lower end, which is placed in a hollow region of the barrel 12.
  • the jacket 42 comprises an upper rim 44 by which it rests on the upper face 22 of the cylinder. barrel.
  • Heating and / or cooling means can therefore be provided for one or more cells.
  • a resistive heating wire 42.1 is preferably wound around the jacket 42. Forced cooling of this jacket 42 is obtained by means of a fan (not shown) placed in the hollow region of the barrel 12, which has an opening 46 in the side face 28, under the cell 15. A series of lamellar openings 48 are also made in the side wall 28 of the barrel 12.
  • each cell 14 with a bottle is equipped with a temperature sensor 19 ( Fig. 4 ).
  • Cell 14.4 can include 2 temperature sensors.
  • a precision balance 21 ( Fig. 4 ) is advantageously provided at the bottom of each cell 14.1 to 14.4.
  • the scales make it possible to know in real time the volume present in each bottle.
  • Means for detecting the angular (clockwise) positioning of the barrel are advantageously provided for increased precision in the positioning of the barrel 12 relative to the orifice 24.
  • Optical means (not shown) are preferred.
  • the barrel is equipped with a barcode determining the position of each cell 14.1 to 14.4 and 15.
  • a bar code reader is placed in the screed 16.
  • This disinfection means can comprise a ramp of UV-emitting lamps around 254 nm (for example LEDs), positioned on the upper circumference (inlet) of the cell and oriented towards the interior of the cell, towards the upper side of the bottle.
  • the ramp of LEDs is indicated as 23 in Fig. 4 .
  • the syringe actuating means 26 which is mounted on the plate 32 at the rear of the barrel 12. It comprises two movable elements 52 and 54 (simply called 'movable') sliding vertically along two fixed axes 56 and 58, smooth and vertical; and driven along these axes 56, 58 by means of two endless screws 60 and 62 formed by threaded rods.
  • Each of the mobiles 52, 54 comprises a horizontal support plate 52.1, 54.1 with two orifices crossed by the sliding axes 56, 58.
  • Each support plate 52.1, 54.1 carries, at the level of the sliding holes, a guide sleeve 64 aligned with this last, to improve horizontal stability when moving along the axes 56, 58.
  • the lower support plate 52.1 comprises an orifice through which the worm 60 passes and a thread formed by a threaded sleeve 66, fixed on the support plate 52.1 and aligned with said orifice.
  • the thread of the sleeve 66 corresponds to that of the worm 60 and therefore allows the ascent or the descent of the support plate 52.1 along the worm 60, depending on the direction of rotation of the screw 60.
  • the screw 60 is driven in rotation by a first motor assembly 67 resting on the plate 32.
  • the upper support plate 54.1 comprises a passage (smooth) opening for the worm 60 which drives the lower support plate 52.1. It further comprises an orifice through which the other endless screw 62 passes, associated with a screw thread formed by a threaded sleeve 68, fixed on the support plate 54.1 and aligned with said orifice.
  • the thread of the sleeve 68 corresponds to that of the worm 62 and therefore allows the ascent or the descent of the plate 54.1 along the screw 62, according to the direction of rotation of the latter.
  • the screw 62 is driven in rotation by a second motor assembly 70 fixed to the lower support plate 52.1.
  • the second motor assembly 70 is preferably fixed under the lower support plate 52.1 and the connection with the worm 62 is made through an orifice made in the plate 52.1.
  • the actuation of the first motor assembly 67 alone allows simultaneous movement of the support plates 52.1 and 54.1, which is useful for moving the entire syringe relative to the barrel.
  • the actuation of the second motor assembly 70 causes a relative movement between the two support plates 52.1 and 54.1, which therefore allows the piston of the syringe to be moved relative to the syringe body.
  • a position sensor for example of the potentiometer type, is advantageously associated with each mobile 52 and 54 in order to determine their respective vertical position with good precision. Knowing the relative displacement between the two moving parts 52, 54 makes it possible to know the stroke of the piston and therefore to calculate the volumes introduced into the syringe body or expelled.
  • each support plate 72 parallel, placed vis-à-vis the longitudinal ends of the support plates 52.1 and 54.1. They each comprise on their inner faces a vertical guide means for the mobiles, here in the form of a vertical rib 74 of triangular profile, placed in the center of the upright. Each support plate comprises at its longitudinal ends a triangular incision 76 of shape corresponding to the ribs 74, to improve the stability of the guide.
  • Each of the two wheels 52, 54 comprises gripping means for the syringe.
  • Reference sign 80 denotes an actuator arm of form triangular, integral with the upper support plate 54.1, projecting from the side of the barrel 12. It ends with a coupling portion 82 with a horizontal groove 84 in which the head of the syringe piston is housed.
  • the arm 80 is slidably mounted on a pair of rails 81 fixed to the second plate 54.1, in order to approach the syringe piston head to engage it, or to move away from it. This movement is controlled by a motor assembly 83 driving an endless screw.
  • the syringe body is for its part received and blocked in the syringe holder 27 associated with the support plate 52.1.
  • the syringe holder 27 comprises, in the manner of a box, a base 86 and a cover 88 pivoting relative to this base by virtue of a lateral hinge 90 ( Figures 8 and 9 ).
  • a latch (not shown - remotely controlled) is provided to hold the cover 88 in the closed position on the base 86.
  • the interior parts facing the base 86 and the cover 88 each comprise a recess so as to define a housing for the base. syringe body, ensuring the maintenance of the syringe body in the horizontal and vertical plane.
  • the recesses 92, 92 ' for the cylindrical syringe body, and horizontal slots 93, 93' to accommodate the end flange of the syringe body.
  • the syringe holder 27 is mounted on a support 94, which slides on two horizontal smooth rods 96, transversely to the vertical axis of movement of the syringe holder 27 by means of the mobiles 52 and 54.
  • the support 94 which for example has the shape of a square plate, comprises on the rear face two cylindrical bearings 98 in which the rods 96 are engaged.
  • the rods 96 are held fixedly parallel at their ends by two arms 100 integral with the support plate lower 52.1.
  • a drive means is provided to move the syringe holder support 94 along the rods 96, making it possible to selectively position the syringe holder 27 on either side of the barrel 12 to bring the syringe to a device or accessory placed just above. side of barrel 12.
  • Reference sign 101 designates a motor assembly attached to the outer side of an arm 100. The drive of the syringe holder holder 94 is moved over the rods 96 by means of a belt (not shown). which is driven by the motor 101 and supported by a pulley (not shown) fixed on the arm 100 opposite the motor 101.
  • the syringe holder 27 is advantageously mounted to move relative to its support 94, in order to be able to lower the syringe holder 27 relative to the vertical position of the lower support plate 52.1.
  • the syringe holder 27 it is possible to move the syringe holder 27 laterally, and lower it, to bring the syringe holder 27 into a counting well (not shown) in order to measure the radioactive dose contained in the syringe.
  • the syringe can also be placed on a collection support.
  • the latter is preferably made of a material which does not block the radiation of radionuclides, for example rigid plastic.
  • the syringe holder 27 is lowered relative to its support 94.
  • the syringe holder 27 is connected to the support 94 by means of two driving links (cables) (not shown) which are actuated by a motor assembly 102.
  • Two Centering cones 104 are arranged vertically and fixed to tabs 106 integral with the upper edge of the support 94.
  • the centering cones 104 cooperate with conical housings 108 in the upper face of the base 86 of the syringe holder 27.
  • the links of drives are guided vertically through a central passage in the centering cones 104 and also pass through the conical housings 108.
  • FIGS. 5 and 6 respectively illustrate a working position and the closed position of the barrel.
  • the barrel 12 is positioned with the housing 14.1 aligned with the opening 24.
  • the door syringe 27 rests on its support 94 and the mobile 52 is in the low position: the needle 110 fixed to the end of the syringe 29 is in the cell 14.1 and is engaged in a bottle 112.
  • the syringe piston 92 it is possible to maneuver the syringe piston 92 using the mobile 54 to withdraw liquid from the vial, or inject a quantity from the syringe into the vial 112.
  • sampling or injection operations can be carried out for a bottle housed in any of the cells 14.1 to 14.4, by aligning the cell with the opening 24, that is to say in the working positions of the barrel 12 .
  • the armored side wall 18, the yoke 16 also comprises a rear wall 18.1, therefore surrounds the entire periphery of the barrel 12.
  • the barrel 12 is in an angular position in which the cell / housing 15 carrying the lead disc 17 is aligned with the opening 24: this is the closed position of the barrel 12.
  • the syringe holder 27 is of course reassembled, to release the syringe 29, respectively the needle, from the orifice 24.
  • the lead disc 17 closes the opening 24, physically blocking communication with the interior of the cap 16, and also blocking the emissions of isotopes through the opening 24.
  • An operator can then handle the syringe holder 27, in particular for the installation of a new syringe, without fear of taking a rate of radioactive doses at the end of his fingers.
  • the device preferably comprises a control module managed by software, preferably external to the device, to control: the rotational movements of the barrel, the movements of the mobiles 52 and 54 and thus keep a history ( log) of the quantities withdrawn, and the movements of the syringe holder 27.
  • a control module managed by software, preferably external to the device, to control: the rotational movements of the barrel, the movements of the mobiles 52 and 54 and thus keep a history ( log) of the quantities withdrawn, and the movements of the syringe holder 27.
  • Example of use of the present device for the preparation of injections of RPM Example of use of the present device for the preparation of injections of RPM.
  • the first vial contains the metastable Technetium 99 isotope (Tc 99m *) initially diluted in 5 ml of aqueous sodium chloride (NaCl).
  • Tc 99m * metastable Technetium 99 isotope
  • a patient dose is of the order of 0.6 GBq.
  • Each type of scintigraphic examination requires its specific marker which will be a vector of technetium towards the region to be explored and therefore its own pot.
  • the device ensures the preparation of two types of markers as soon as it is necessary, and once at the beginning of the shift.
  • the second vial contains the NaCl needed to make dilutions.
  • the third vial will become the bone marker for bone scintigraphy.
  • a vial as sold filled with HDP (Hydroxidiphosphonate (HDP) / Osteocis) in powder form is initially loaded into the blister.
  • the device 10 is responsible for filling this third vial with the solution of Tc + NaCl.
  • the barrel 12 is then rotated to facilitate dilution of the powder in Tc + NaCl.
  • the ideal volume activity is 750Mbq / mL.
  • the fourth vial will become the cardiac marker for cardiac scintigraphy.
  • a vial as sold filled with mibi (sestamiBi) in powder form is initially loaded into the cell, in particular cell 14.4.
  • the device is responsible for filling this fourth flask with the Tc + NaCl solution.
  • the barrel 12 is then rotated to facilitate dilution of the powder in Tc + NaCl.
  • the heating function of the cell 14.4 is also activated.
  • the ideal volume activity is 260Mbq / mL.
  • the prescriptions of the vector manufacturers will generally be followed.
  • the scales allow the device in real time to know the volume present in each vial, the heating device only concerns the cardiac marker (mibi). Before labeling, the device will take NaCl in the dedicated vial to dilute the source pot, then take from this source pot, the activity necessary to inject to perform a reconstitution (labeling) of a kit according to the activity of the day or user request.
  • Fractionation the dose to be prepared for the patient is unique and depends on the patient's weight. It is read by the operator from a weight-dose chart.
  • the operator takes in a syringe, and according to his experience, a volume of radioactive drug in a source jar corresponding at first sight to the need for product according to the weight of the patient then measures the dose contained in the syringe in a counting well that will measure the radioactivity. If the “amount” of radioactivity does not correspond to what is needed by the patient, it is necessary, in conventional preparation methods, to make a manual adjustment of the dose present in the syringe to or from the source pot and repeat the procedure. measurement as many times as necessary to arrive at a measurement corresponding to the quantity of radioactivity required by the patient.
  • the fractionation is greatly facilitated by the present device 10. Knowing the volume and activity in the source pot, the device 10 does not need to perform the "round trips" described above, and samples. from the outset, in the requested kit, the volume corresponding to the requested activity. Then, the syringe is measured in a counting well contained in the preparation chamber thanks to the lateral translation on the rods 96, before being placed in a protective tungsten case, when the preparation is finished.
  • the invention is not limited to the embodiment which has just been described by way of example, but covers all the variants thereof.
  • the barrel 12 is a particular embodiment of a mobile support block, but could take other forms to perform the function of receptacle for bottles with its cells / wells.

Landscapes

  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Mechanical Engineering (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Sampling And Sample Adjustment (AREA)
EP17811538.2A 2016-12-07 2017-12-05 Dispositif de préparation de solutions radioactives Active EP3551538B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1662069A FR3059567B1 (fr) 2016-12-07 2016-12-07 Dispositif de preparation de solutions radioactives
PCT/EP2017/081532 WO2018104306A1 (fr) 2016-12-07 2017-12-05 Dispositif de préparation de solutions radioactives

Publications (2)

Publication Number Publication Date
EP3551538A1 EP3551538A1 (fr) 2019-10-16
EP3551538B1 true EP3551538B1 (fr) 2021-02-03

Family

ID=58645141

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17811538.2A Active EP3551538B1 (fr) 2016-12-07 2017-12-05 Dispositif de préparation de solutions radioactives

Country Status (6)

Country Link
US (1) US10755828B2 (es)
EP (1) EP3551538B1 (es)
JP (1) JP2020500642A (es)
ES (1) ES2868787T3 (es)
FR (1) FR3059567B1 (es)
WO (1) WO2018104306A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109896054A (zh) * 2019-03-25 2019-06-18 常州市第二人民医院 一种放射性药物微辐射分装装置
EP3754383A1 (en) * 2019-06-18 2020-12-23 Université de Lorraine Device for the preparation of radioactive solutions
CN115367234B (zh) * 2022-10-10 2023-01-31 山东省蓬莱制药机械厂有限公司 一种西林瓶规格可调式全自动药粉灌装机

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE902407R (fr) * 1984-10-19 1985-09-02 Karlsruhe Wiederaufarbeit Dispositif de prelevement d'echantillons notamment pour des substances toxiques et/ou radio-actives.
US7750328B2 (en) * 2006-10-27 2010-07-06 Draximage General Partnership Filling system for potentially hazardous materials

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
WO2018104306A1 (fr) 2018-06-14
FR3059567B1 (fr) 2018-11-30
EP3551538A1 (fr) 2019-10-16
US10755828B2 (en) 2020-08-25
FR3059567A1 (fr) 2018-06-08
JP2020500642A (ja) 2020-01-16
ES2868787T3 (es) 2021-10-21
US20190341162A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
EP3551538B1 (fr) Dispositif de préparation de solutions radioactives
US20100331600A1 (en) System for dispensing radio-pharmaceuticals and measuring radiation dosage of it
CA2624744C (en) Filling system for potentially hazardous materials
EP2179926B1 (fr) Dispositif stérile à usage unique de préparation d'un médicament radiopharmaceutique, système et procédé mettant en oeuvre ce dispositif
US5479969A (en) Apparatus for dispensing substances which are biologically hazardous
RU2110214C1 (ru) Устройство для раздачи биологически вредных веществ
FR2906475A1 (fr) Unite medicale pour le prelevement,le calibrage,la dilution et/ou l'injection d'un produit radioactif injectable
AU2003209692B2 (en) Container for vial of radiopharmaceutical and set for its infusion in a patient or for its transfer elsewhere
WO2011092427A1 (fr) Machine pour remplir une pluralite de recipients, systeme incluant une telle machine et procede de fabrication afferent
JP2009502344A (ja) カウンターフォースアクセス機構、システム、及び方法を備えた放射性医薬品の調剤装置
WO1994004415A1 (en) Apparatus for dispensing substances which are biologically hazardous
EP2668101B1 (fr) Dispositif sterile a usage unique de mise en seringues de medicaments radiopharmaceutiques, systeme automatique et procede de mise en seringues mettant en oeuvre ce dispositif
FR2739565A1 (fr) Procede et installation de preparation d'une solution injectable radioactive
JP5746552B2 (ja) バイアルシールド
FR2956091A1 (fr) Dispositif sterile a usage unique de mise en seringue de medicaments radiopharmaceutiques, systeme semi-automatique et procede de mise en seringues mettant en œuvre ce dispositif
WO2008117097A2 (en) Filling system for potentially hazardous materials
CN216035883U (zh) 一种防污染的检验科护理用安全型送检装置
WO2013045421A1 (en) Device

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190614

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THOMAS, QUENTIN

Inventor name: MATHIAS-LAOT, GUENOLE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20200717

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1359654

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017032361

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: OFFICE ERNEST T. FREYLINGER S.A., CH

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1359654

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210503

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210504

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210503

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210604

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210603

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2868787

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20211021

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017032361

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20211104

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20211231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211205

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20171205

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231128

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231127

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231201

Year of fee payment: 7

Ref country code: FR

Payment date: 20231127

Year of fee payment: 7

Ref country code: DE

Payment date: 20231128

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240118

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210203

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240101

Year of fee payment: 7